Company

Replimune Group, Inc.

Headquarters: Woburn, MA, United States

Employees: 152

CEO: Mr. Philip Astley-Sparke FSA

NASDAQ: REPL -0.80%

Market Cap

$498.1 Million

USD as of July 1, 2024

Market Cap History

Replimune Group, Inc. market capitalization over time

Evolution of Replimune Group, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Replimune Group, Inc.

Detailed Description

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Replimune Group, Inc. has the following listings and related stock indices.


Stock: NASDAQ: REPL wb_incandescent

Stock: FSX: 7R8 wb_incandescent

Stock: Munich: 7R8 wb_incandescent

Details

Headquarters:

500 Unicorn Park

3rd Floor

Woburn, MA 01801

United States

Phone: 781 222 9600